New technologies based on human cells are increasingly seen as key to reducing the time and cost in bringing drugs to market. This is an evolving area of study, though the field itself, which developed out of study into 3D cell architecture, is not new. These approaches replicate human physiology to study diseases, treatments, and for drug-development purposes. In parallel to major advances made from a medical and scientific standpoint, novel legal and ethical questions arise.
The definition of organoid is problematic and covers a range of cell culture techniques. Scientists have developed ways of culturing organ-specific tissue from human stem cells or progenitor cells to re-create important aspects of the 3D anatomy e.g. the pancreas, kidney, liver, thyroid, retina, and brain, to recapitulate key organ features. A list of definitions can be found at the end of this article.
A potential game-changer
Breakthroughs in stem cell technology and tissue engineering are driving the change. In addition to this, trends in other areas, like cell and gene therapy and personalised medicine have acted as catalysts. By simulating organ function, specific disease states can be modelled and studied. This is especially useful when looking at rare diseases, how tissue and microbiota interact, or how drugs interact with each other.
The use of organoids holds great promise in several medical-scientific areas like disease modelling, precision medicine, and transplantation. One of the most notable possibilities is to supplement or to a certain extent replace animal models during pre-clinical studies in drug development.
The field is at an early stage, but the trend is an upward one. Companies involved are seeing increasing demand for their services from pharma, biotech, research and academic institutes as well as the cosmetics industry. According to a recent market report the annual growth rate is set to increase by 37.4% during 2022-2028. Cambridge-based CN Bio recently doubled the size of its laboratory facilities due to demand. In the US, Hesperos Inc., a contract research organisation (CRO) provides a multi-organ chip platform (Human-on-a-Chip) based in Florida filed for a USD 20 million IPO. Another fascinating company is Labskin, who make full thickness human skin models, providing reproduceable results for microbiome research. Labskin just announced the first ever commercially available pigmented skin-equivalent in a joint project with Bradford University. These new models incorporate melanocytes, the cells that give skin its colour and present a huge opportunity to study melanomas.
The need for new and/or updated regulatory frameworks
For the use of these new models to be considered by regulatory authorities across the globe in the evaluation of safety and efficacy of drugs (subject to valid scientific demonstrations), regulatory frameworks will have to be adapted on a jurisdiction-by-jurisdiction basis.
In the US, the FDA Modernization Act of 2021 has been introduced to amend the Federal Food, Drug, and Cosmetic Act. The amendment strikes animal and inserts nonclinical tests or studies to be used in the evaluation of safety and efficacy of drugs, such as MPS, cell-based assays and computer models. In addition, the FDA recently approved the first clinical trial using efficacy data collected from a microphysiological system. More data may be needed to convince regulators, but the impetus - and interest - is there.
In the EU, is a 3-year Science With and For Society (SwafS) project, funded under HORIZON2020. The project is being coordinated by the University of Oslo, Norway and involves major research institutions across the EU. It is currently being carried out with the objective of developing a comprehensive regulatory framework for organoid research and organoid-related technologies. In the meantime, the European Parliament is working on legislation aimed at reducing the number of animal studies. The European Medicines Agency already recognized that organoids and organ-on-chip may become suitable alternatives to animal models during medicines development, in its wider effort to promote the 3R principles (replace, reduce and refine).
Further legal and ethical challenges to be addressed
The use of organoids and other MPS raises critical legal and ethical issues, which must be urgently addressed to allow their wide-spread utilization as part of pre-clinical studies within an acceptable framework.
In particular, since organoids are grown from human cells, initial donors rights must be respected and efficiently enforced. The original cells may come from foetal or adult tissues they may be pluripotent stem cells (PSCs), adult stem cells taken from specific tissues and reengineered somatic cells. Key challenges notably relate to the donors informed consent, (which issue has already been addressed by many scholars), research on human embryos and data protection issues. Complete anonymity of human tissue has been shown to be neither possible (due to the identifiable nature of DNA) nor desirable (as the data is necessary to validate prediction models). The donor must be able to control, to some extent, the subsequent use of his/her samples; in practice, consent may not be easily withdrawn (or with very limited effect) once organoids have been successfully developed and used in a pre-clinical study.
Strong quality standards should further be developed and complied with when it comes to producing organoids for pre-clinical purposes. Indeed, a set of specifications for the production of human 3D organoids used as medicines has been proposed. One could imagine specific guidelines applicable to the production of organoids for drug development purposes, to ensure consistent production methods as well as reliability as pre-clinical models. This calls for a wider systemic approach as to the regulation of human tissue and cells intended for human versus research application. On this point, it is interesting to note that a proposal for a regulation on standards of quality and safety for substances of human origin intended for human application is currently being examined in the EU, which expressly excludes their use in research that does not involve application to the human body.
Moreover, specific issues are triggered depending on the type of laboratory-cultivated model. For instance, the development of human cerebral organoids raises questions in terms of moral status and legal protection. Indeed, studies suggest that developed neuronal models show complex electrical activity the human cerebral organoids (sometimes referred to as mini-brains) can command a muscle connected thereto, be receptive to stimuli and may even exhibit a rudimentary form of consciousness. This raises questions as to the core definition of human being and, from a legal standpoint, personhood, the beginning and end of life, as well as the legal protection that should be awarded to such in vitro models (how they can be engineered, used, destroyed etc). In addition, the existence of sophisticated sentient models creates uncertainty regarding what moral status should be awarded to them. These issues are particularly complex as legal, ethical, philosophical, societal and political aspects are necessarily intertwined, and the way they are addressed may greatly vary from one jurisdiction to another.
Further legal and ethical challenges should be addressed in connection with the production and use of organoids beyond pre-clinical studies such as their potential patentability, their commercialization (while certain countries like France forbids the commercialization of human products and elements), their use for transplantation, the articulation with regulations on genome editing, chimeras and human cloning etc.
Conclusion
The rapid progress of scientific research around organoids and other MPS bears the potential to revolutionize many aspects of medical and pharmaceutical research. In particular, they hold great promise in the pursuit of a suitable (and potentially more reliable) alternative to the use of animal models in pre-clinical studies. Beyond this, legal and ethical challenges should be addressed in connection with the production and use of organoids in other applications such as their potential patentability, their commercialization (while certain countries like France forbids the commercialization of human products and elements), their use for transplantation, and the articulation with the regulations on genome editing, the creation of chimeras and human cloning.
Definitions:
Microphysiological systems (MPS): an umbrella term for organ-on-chip (OOC), organoids or tumoroids (stem cells grown in a dish).
Organ-on-a-chip (OOC): from the field of microfluidics, a multi-channel 3-D cell culture. An integrated circuit that simulates the activities, mechanics and physiological response of an entire organ or an organ system.
Organoid: means resembling an organ. Organoids are defined by three characteristics. The cells arrange themselves in vitro into three-dimensional organization that is characteristic for the organ in vivo, the resulting structure consists of multiple cells found in that particular organ and the cells execute at least some of the functions that they normally carry out in that organ.
Visit link:
Organoids: science fiction or the future of pre-clinical studies? - Lexology
- Researchers develop method to study brain connectivity, functionality - Florida Hospital News and Healthcare Report - South Florida Hospital News - October 13th, 2022
- A win for stem cells | Washington Examiner - October 4th, 2022
- TransMedia Group to Illumine Impressive Neuro Healing Results Achieved by Raymond Cralle, a Pioneer in Hyperbaric Oxygen Therapy and a Florida... - September 16th, 2022
- Sure Signs You Have Non-Hodgkin's Lymphoma Eat This Not That - Eat This, Not That - August 22nd, 2022
- New treatment changing outlook for those with blood cancers - WBAL TV Baltimore - July 19th, 2022
- Engineering Graduate Fellows Get Hands-on Experience with National Industry Leaders - UCF - July 11th, 2022
- New Alzheimer's Treatment on Horizon as Dementia Reversed for First Time in Dogs - StreetInsider.com - June 22nd, 2022
- Life Cycle of a Moss - Infographic - STEM Lounge - June 13th, 2022
- Miller School Researchers on the Trail to Unraveling Long COVID-19 - Florida Hospital News and Healthcare Report - South Florida Hospital News - June 4th, 2022
- American Academy of Stem Cell Physicians is Proud to Add to the Speaker Roster, Dr. Scheffer Tseng, Acclaimed Opthamologist and Founder of Bio-Tissue... - May 15th, 2022
- 'Doctors gave me six months to live in 2016 but I continue to defy every expectation' - Wales Online - May 2nd, 2022
- Revolutionary Oxygen Healing Therapy Now Available in Florida - Digital Journal - March 25th, 2022
- Global Mesenchymal Stem Cells Market Analysis, Opportunities, Trend and Forecast To 2029 Discovery Sports Media - Discovery Sports Media - January 20th, 2022
- EDUCATION SPOTLIGHT: Florida Tech Highlights Work Done During 2021 as We Enter the New Year - SpaceCoastDaily.com - January 5th, 2022
- Roundtable Discussion: Shain Looks at the Role of Transplant Eligibility in Patients With Newly Diagnosed Multiple Myeloma - Targeted Oncology - November 8th, 2021
- ALS and dementia attacked by an RNA-hunting compound that recruits cell's own virus fighter - EurekAlert - October 28th, 2021
- Brainstorm Cell, (BCLI) falls 0.65% in Active Trading on October 25 - Equities.com - October 28th, 2021
- Global Mesenchymal Stem Cells Market Prospects, Upcoming Trends and Competitive Outlook till 2028 | Lonza, Thermo Fisher, Bio-Techne, ATCC,... - October 28th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WWNY - October 5th, 2021
- US FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | DNA RNA and... - October 5th, 2021
- Times really up! FDA authority to crack down on regenerative medicines upheld as grace period ends - JD Supra - July 21st, 2021
- Animal Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 - The Courier - March 11th, 2021
- An 8-year-olds search for bone marrow match in battle with leukemia comes to North Texas - The Dallas Morning News - March 11th, 2021
- Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd. - PRNewswire - March 11th, 2021
- How soon will COVID-19 vaccines return life to normal? - Science Magazine - February 16th, 2021
- Keep it Flowing: Combating COVID-19 Blood Shortages in Cancer Treatment - Curetoday.com - February 16th, 2021
- FL Doctors Make Breakthrough Using Stem Cells to Treat ... - February 2nd, 2021
- This Guy Injected His Dick With Stem Cells to Try to Make ... - February 2nd, 2021
- 10 Best Stem Cell Beauty Products On The Market Today - February 2nd, 2021
- HealthLynked's The Future of Healthcare Summit Brings Healthcare Experts and Technology Innovators from Around the World to Naples, Florida -... - February 2nd, 2021
- SpaceX Cargo Dragon Returning To Earth; First U.S. Commercial Cargo Craft To Return From ISS - Science Times - January 8th, 2021
- Buoyed by study, scientists increasingly hopeful first two COVID-19 vaccines effective against new strains - The Boston Globe - January 8th, 2021
- Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all - Study Finds - December 23rd, 2020
- Flavours added to vaping devices can damage the heart: Study - Sify News - December 12th, 2020
- Jabbed for a good cause: Hundreds already getting COVID-19 shots as part of clinical trial - The West Volusia Beacon - August 29th, 2020
- Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -... - June 8th, 2020
- Hesperos Human-on-a-Chip System Used to Model Preclinical Stages of Alzheimers Disease and Mild Cognitive Impairment - Yahoo Finance - June 4th, 2020
- Can genetics explain the degrees of misery inflicted by the coronavirus? - Genetic Literacy Project - April 21st, 2020
- Beating cancer by taking the unbeaten path | ASU Now: Access, Excellence, Impact - ASU Now - April 9th, 2020
- Reviewing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) - Redmond Register - March 26th, 2020
- Head to Head Analysis: Harsco (NYSE:HSC) & CRYO-CELL International (NYSE:CCEL) - Redmond Register - March 24th, 2020
- Reviewing Harsco (NYSE:HSC) and CRYO-CELL International (NYSE:CCEL) - Redmond Register - March 12th, 2020
- Data On Enlivex's Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation... - February 24th, 2020
- Consistent Outcomes Using Ryoncil as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD - BioSpace - February 24th, 2020
- NASA to send equipment to International Space Station to research Improving Shoes, Showers, 3D Printing - Clarksville Online - February 24th, 2020
- Here are all the science projects that SpaceX will deliver to the ISS - Digital Trends - February 24th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 24th, 2020
- 'Florida cold' and the semi-glamorous world of work trips - CT Insider - February 19th, 2020
- 34 Years with a New Heart and Counting | 90.1 FM WABE - WABE 90.1 FM - February 19th, 2020
- Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime - National Institutes of Health - February 16th, 2020
- Research - Florida Stem Cell Research - January 3rd, 2020
- Florida Stem Cell Treatment Center - January 3rd, 2020
- Advances In Treatment Of Soft Tissue Injuries (Video) - South Florida Reporter - January 3rd, 2020
- Explained: What is the water crisis Southwest Florida is battling? - Wink News - December 24th, 2019
- Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment - The Sun - December 1st, 2019
- World AIDS Day 2019: Theme, History and Facts about HIV and AIDS - Newsweek - December 1st, 2019
- Tulane team researching ways to end opioid addiction - News from Tulane - November 24th, 2019
- Improve global wellbeing with a degree in public health - Study International News - November 12th, 2019
- Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting - GlobeNewswire - November 12th, 2019
- Reviewing US Stem Cell (OTCMKTS:USRM) and Auxly Cannabis Group (OTCMKTS:CBWTF) - Riverton Roll - November 12th, 2019
- Bloomington Vet Joins Study For Stem Cell Therapy To Treat Dogs With Arthritis - WGLT News - October 24th, 2019
- Brooks Koepka Withdraws in Korea After Reaggravating Knee Injury - Golf Channel - October 24th, 2019
- Walking in His Shoes - Curetoday.com - October 5th, 2019
- The Real Problem With Beef - The New York Times - October 2nd, 2019
- Stem Cell Treatment Clinic St. Augustine - Florida Stem Cell - March 17th, 2019
- Stem Cell Questions - Florida Stem Cell - FAQs - February 2nd, 2019
- Stem Cell Procedure for Erectile Dysfunction - January 26th, 2019
- Stuart Florida Stem Cells | NovaGenix - January 18th, 2019
- Stem Cell Hair Treatment for Hair Loss | Stem Cell Hair Growth - January 3rd, 2019
- South Florida Stem Cell Center | Melvin M. Propis, M.D. - December 11th, 2018
- Florida Stem Cell Treatments - Regenerative Orthopedic ... - December 11th, 2018
- Florida - Stem Cells Transplant Institute - July 24th, 2018
- FDA: Florida Stem Cell Clinic Violates Law | Health News ... - October 18th, 2017
- Stem cell research | UF Health, University of Florida Health - October 18th, 2017
- FDA: Serious Problems at Florida Stem Cell Clinic - WebMD - August 29th, 2017
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - KRCB - August 29th, 2017
- US FDA steps up scrutiny of stem cell therapies - Reuters - August 29th, 2017
- Paralyzed After Pool Accident, Student Heads Back To College - News Talk Florida - August 29th, 2017
- SpaceX to Launch NASA Cargo, Try Rocket Landing Today: Watch It Live - Space.com - August 16th, 2017
- Dragon Splashes Down to Complete Resupply Mission - Space Daily - July 7th, 2017